MGMT and glioblastoma: Of the very few biomarkers that are used clinically in GBM today, the DNA repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation predicting response to chemotherapy is the one that is the most implemented but is not used very actively, as there is a lack of treatment options.